

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application.

LISTING OF CLAIMS:

Claims 1 to 48 (Canceled)

49. (Currently amended) A vaccine comprising a recombinant attenuated respiratory syncytial virus, the genome of which contains the reverse complement of an mRNA coding sequence operatively linked to a polymerase binding site of a respiratory syncytial virus, and a pharmaceutically acceptable carrier, wherein the genome comprises a genetic alteration wherein the genetic alteration is a deletion of the NS1 gene.

Claim 50. (Canceled)

51. (Previously presented) The vaccine of claim 49, wherein the genetic alteration is in a regulatory domain.

52. (Previously presented) The vaccine of claim 49, wherein the genetic alteration is in a functional domain.

53. (Previously presented) The vaccine of claim 49, wherein the virus is capable to go through only one round of replication in the host.

54. (Canceled)

55. (Canceled)

56. (Previously presented) The vaccine of claim 49, wherein the genetic alteration is a deletion of one or more nucleotides.

57. (Currently amended) An immunogenic composition comprising a recombinant attenuated respiratory syncytial virus, the genome of which contains the reverse complement

of an mRNA coding sequence operatively linked to a polymerase binding site of a respiratory syncytial virus, and a pharmaceutically acceptable carrier, wherein the genome comprises a genetic alteration wherein the genetic alteration is a deletion of the NS1 gene.

58. (Currently amended) An immunogenic composition comprising a recombinant attenuated respiratory syncytial virus, the genome of which contains the reverse complement of an mRNA coding sequence operatively linked to a polymerase binding site of a respiratory syncytial virus, and a pharmaceutically acceptable carrier, wherein the genome comprises a modification not found in the genome of native RSV, wherein the modification is a deletion of the NS1 gene.

59. (Canceled)

60. (Canceled)

61. (Previously presented) The immunogenic composition of claim 57, wherein the genetic alteration is a deletion of one or more nucleotides.

62. (Previously presented) The immunogenic composition of claim 57, wherein the genetic alteration is in a regulatory domain.

63. (Previously presented) The immunogenic composition of claim 57, wherein the genetic alteration is in a functional domain.

64. (Canceled)

65. (Canceled)

66. (Previously presented) The immunogenic composition of claim 58, wherein the modification is a deletion of one or more nucleotides.

67. (Previously presented) The immunogenic composition of claim 58, wherein the modification is in a regulatory domain.

68. (Previously presented) The immunogenic composition of claim 58, wherein the modification is in a functional domain.

69. (Previously presented) The immunogenic composition of claim 57 or 58, wherein the virus is capable to go through only one round of replication in the host.

70. (Previously presented) A vaccine comprising the immunogenic composition of claim 57, 58, 61, 62, 63, 66, 67, or 68.

71. (Previously presented) A vaccine comprising the immunogenic composition of claim 69.

72. (Canceled) ~~The immunogenic composition of claim 57 or 58, wherein the modification affects at least one of the following the M2-2 open reading frame, the SH gene, the NS1 gene, and the NS2 gene.~~

73. (Currently amended) A pharmaceutical composition comprising (1) a recombinant attenuated respiratory syncytial virus, the genome of which contains the reverse complement of an mRNA coding sequence operatively linked to a polymerase binding site of a respiratory syncytial virus, and a pharmaceutically acceptable carrier, wherein the genome comprises a genetic alteration wherein the genetic alteration is a deletion of the NS1 gene; and (2) a pharmaceutically acceptable carrier.

74. (Currently amended) A pharmaceutical composition comprising (1) a recombinant attenuated respiratory syncytial virus, the genome of which contains the reverse complement of an mRNA coding sequence operatively linked to a polymerase binding site of a respiratory syncytial virus, and a pharmaceutically acceptable carrier, wherein the genome comprises a modification not found in the genome of native RSV, wherein the modification is a deletion of the NS1 gene; and (2) a pharmaceutically acceptable carrier.

75. (Canceled)

76. (Currently amended) The pharmaceutical composition of claim 73 ~~[[732]]~~, wherein the genetic alteration is a deletion of one or more nucleotides.

77. (Previously presented) The pharmaceutical composition of claim 73, wherein the genetic alteration is in a regulatory domain.

78. (Previously presented) The pharmaceutical composition of claim 73, wherein the genetic alteration is in a functional domain.

79. (Canceled)

80. (Previously presented) The pharmaceutical composition of claim 74, wherein the modification is a deletion of one or more nucleotides.

81. (Previously presented) The pharmaceutical composition of claim 74, wherein the modification is in a regulatory domain.

82. (Previously presented) The pharmaceutical composition of claim 74, wherein the modification is in a functional domain.

83. (Previously presented) The pharmaceutical composition of claim 73 or 74, wherein the virus is capable to go through only one round of replication in the host.